Literature DB >> 2146882

Early accumulation of heparan sulfate in neurons and in the beta-amyloid protein-containing lesions of Alzheimer's disease and Down's syndrome.

A D Snow1, H Mar, D Nochlin, R T Sekiguchi, K Kimata, Y Koike, T N Wight.   

Abstract

A monoclonal antibody (HK-249) that recognizes a glucosamine sulfate alpha 1----4 glucuronic acid-containing determinant in heparan sulfate (HS) chains of a basement membrane-derived heparan sulfate proteoglycan identified and immunolocalized HS specifically to the amyloid deposits in neuritic plaques (NPs), congophilic angiopathy (CA), as well as in neurofibrillary tangles (NFTs) and non-tangle-bearing neurons in the brains of Alzheimer's and Down's syndrome (DS) patients. Ultrastructural immunohistochemistry demonstrated that HS within neurons of Alzheimer's disease (AD) brain was localized to lipofuscin granules, an aging pigment previously shown also to contain beta-amyloid protein (BAP). Heparan sulfate also was localized to neurite-containing, nonfibrillar 'primitive' plaques that also demonstrated positive BAP immunoreactivity in both AD and DS brains. Antibodies to laminin, fibronectin, and a chondroitin sulfate proteoglycan failed to show positive immunostaining of the HS-containing sites described above. Analysis of DS patients at different ages revealed that HS accumulated within neurons of the hippocampus and amygdala as early as 1 day after birth. Young age-matched controls did not demonstrate similar positive HS immunoreactivity in neurons, whereas positive immunostaining for HS was observed in other regions thought to normally contain HS. The earliest deposition of BAP was first observed as 'amorphous' or 'diffuse' cortical deposits in DS brain in patients aged 18 and 24 years before the accumulation of fibrillar amyloid (observed in DS patients who are 35 years and older). These cortical deposits also contained positive HS immunoreactivity, implying that HS accumulation in conjunction with the BAP is an early event that ultimately may contribute to the early age-related accumulation (ie, as early as 35 years of age in DS) of NPs, NFTs, and/or CA. Furthermore the colocalization of HS and BAP in a number of specific locales in AD and DS brain indicates a possible interaction between these two macromolecules that may be important in lesion development in these two diseases.

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 2146882      PMCID: PMC1877656     

Source DB:  PubMed          Journal:  Am J Pathol        ISSN: 0002-9440            Impact factor:   4.307


  65 in total

1.  A quantitative study of lipofuscin accumulation with age in normals and individuals with Down's syndrome, phenylketonuria, progeria and transneuronal atrophy.

Authors:  C D West
Journal:  J Comp Neurol       Date:  1979-07-01       Impact factor: 3.215

2.  Alzheimer neurofibrillary tangles contain phosphorylated and hidden neurofilament epitopes.

Authors:  M C Haugh; A Probst; J Ulrich; J Kahn; B H Anderton
Journal:  J Neurol Neurosurg Psychiatry       Date:  1986-11       Impact factor: 10.154

3.  Induction of secretion of IgM from cells of the B cell line 38c-13 by somatic cell hybridization.

Authors:  Z Eshhar; C Blatt; Y Bergman; J Heimovich
Journal:  J Immunol       Date:  1979-06       Impact factor: 5.422

4.  The amyloid deposits in Alzheimer's disease: their nature and pathogenesis.

Authors:  G G Glenner; C W Wong; V Quaranta; E D Eanes
Journal:  Appl Pathol       Date:  1984

5.  Relationship between pigment accumulation and age in Alzheimer's disease and Down syndrome.

Authors:  D M Mann; P O Yates; B Marcyniuk
Journal:  Acta Neuropathol       Date:  1984       Impact factor: 17.088

6.  Lipofuscin pigment accumulation in human brain during aging.

Authors:  V K Goyal
Journal:  Exp Gerontol       Date:  1982       Impact factor: 4.032

7.  Protease-nexin: a cellular component that links thrombin and plasminogen activator and mediates their binding to cells.

Authors:  J B Baker; D A Low; R L Simmer; D D Cunningham
Journal:  Cell       Date:  1980-08       Impact factor: 41.582

8.  Neuronal lipofuscin accumulation in ageing and alzheimer dementia: a pathogenic mechanism?

Authors:  J H Dowson
Journal:  Br J Psychiatry       Date:  1982-02       Impact factor: 9.319

9.  Circular-dichroism studies on two murine serum amyloid A proteins.

Authors:  W D McCubbin; C M Kay; S Narindrasorasak; R Kisilevsky
Journal:  Biochem J       Date:  1988-12-15       Impact factor: 3.857

10.  Changes in nerve cells of the nucleus basalis of Meynert in Alzheimer's disease and their relationship to ageing and to the accumulation of lipofuscin pigment.

Authors:  D M Mann; P O Yates; B Marcyniuk
Journal:  Mech Ageing Dev       Date:  1984 Apr-May       Impact factor: 5.432

View more
  55 in total

1.  Neurotoxicity of the 22 kDa thrombin-cleavage fragment of apolipoprotein E and related synthetic peptides is receptor-mediated.

Authors:  M Tolar; M A Marques; J A Harmony; K A Crutcher
Journal:  J Neurosci       Date:  1997-08-01       Impact factor: 6.167

2.  Agrin is a major heparan sulfate proteoglycan accumulating in Alzheimer's disease brain.

Authors:  M M Verbeek; I Otte-Höller; J van den Born; L P van den Heuvel; G David; P Wesseling; R M de Waal
Journal:  Am J Pathol       Date:  1999-12       Impact factor: 4.307

Review 3.  Sulfated glycosaminoglycans in protein aggregation diseases.

Authors:  Kazuchika Nishitsuji; Kenji Uchimura
Journal:  Glycoconj J       Date:  2017-04-11       Impact factor: 2.916

4.  Beta protein immunoreactivity is found in the majority of neurofibrillary tangles of Alzheimer's disease.

Authors:  G Perry; P Cras; S L Siedlak; M Tabaton; M Kawai
Journal:  Am J Pathol       Date:  1992-02       Impact factor: 4.307

5.  Inhibitors of myelination: ECM changes, CSPGs and PTPs.

Authors:  Danielle E Harlow; Wendy B Macklin
Journal:  Exp Neurol       Date:  2013-11-04       Impact factor: 5.330

Review 6.  The tauopathies: toward an experimental animal model.

Authors:  M Goedert; M Hasegawa
Journal:  Am J Pathol       Date:  1999-01       Impact factor: 4.307

7.  Effects of transforming growth factor-beta (isoforms 1-3) on amyloid-beta deposition, inflammation, and cell targeting in organotypic hippocampal slice cultures.

Authors:  M E Harris-White; T Chu; Z Balverde; J J Sigel; K C Flanders; S A Frautschy
Journal:  J Neurosci       Date:  1998-12-15       Impact factor: 6.167

8.  Colocalization of cholinesterases with beta amyloid protein in aged and Alzheimer's brains.

Authors:  M A Morán; E J Mufson; P Gómez-Ramos
Journal:  Acta Neuropathol       Date:  1993       Impact factor: 17.088

9.  Polarized secretion of beta-amyloid precursor protein and amyloid beta-peptide in MDCK cells.

Authors:  C Haass; E H Koo; D B Teplow; D J Selkoe
Journal:  Proc Natl Acad Sci U S A       Date:  1994-02-15       Impact factor: 11.205

Review 10.  The pathogenic implication of abnormal interaction between apolipoprotein E isoforms, amyloid-beta peptides, and sulfatides in Alzheimer's disease.

Authors:  Xianlin Han
Journal:  Mol Neurobiol       Date:  2010-01-07       Impact factor: 5.590

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.